Evidence map›Paper›PMID 40193392›Full record

ArticleBioinformatics (Oxford, England)2025

Topology-driven negative sampling enhances generalizability in protein-protein interaction prediction.

Ayan Chatterjee, Babak Ravandi, Parham Haddadi, Naomi H Philip, Mario Abdelmessih, William R Mowrey, Piero Ricchiuto, Yupu Liang, Wei Ding, Juan Carlos Mobarec and 1 more

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ayan ChatterjeeBioClarity AI, Boston, MA 02130, United States.ORCID 0000-0002-8662-4863
Babak RavandiBioinformatics and Data Science, Alexion AstraZeneca Rare Disease, Boston, MA 02210, United States.ORCID 0000-0003-0203-5605
Parham HaddadiBioinformatics and Data Science, Alexion AstraZeneca Rare Disease, Boston, MA 02210, United States.ORCID 0000-0002-1876-4055
Naomi H PhilipBioinformatics and Data Science, Alexion AstraZeneca Rare Disease, Boston, MA 02210, United States.ORCID 0000-0002-1475-8635
Mario AbdelmessihBioinformatics and Data Science, Alexion AstraZeneca Rare Disease, Boston, MA 02210, United States.ORCID 0000-0003-2887-5741
William R MowreyBioinformatics and Data Science, Alexion AstraZeneca Rare Disease, Boston, MA 02210, United States.ORCID 0000-0001-9531-9409
Piero RicchiutoBioinformatics and Data Science, Alexion AstraZeneca Rare Disease, Boston, MA 02210, United States.ORCID 0000-0002-8525-6624
Yupu LiangBioinformatics and Data Science, Alexion AstraZeneca Rare Disease, Boston, MA 02210, United States.
Wei DingBioinformatics and Data Science, Alexion AstraZeneca Rare Disease, Boston, MA 02210, United States.
Juan Carlos MobarecProtein Structure and Biophysics, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0001-9482-4294
Tina Eliassi-RadNetwork Science Institute, Northeastern University, Boston, MA 02115, United States.

Funding

Department of Bioinformatics and Data Sciences at Alexion AstraZeneca Rare Disease, Boston, USA
6 · The paper itself

Abstract

motivationUnraveling the human interactome to uncover disease-specific patterns and discover drug targets hinges on accurate protein-protein interaction (PPI) predictions. However, challenges persist in machine learning (ML) models due to a scarcity of quality hard negative samples, shortcut learning, and limited generalizability to novel proteins.

resultsIn this study, we introduce a novel approach for strategic sampling of protein-protein noninteractions (PPNIs) by leveraging higher-order network characteristics that capture the inherent complementarity-driven mechanisms of PPIs. Next, we introduce Unsupervised Pre-training of Node Attributes tuned for PPI (UPNA-PPI), a high throughput sequence-to-function ML pipeline, integrating unsupervised pre-training in protein representation learning with Topological PPNI (TPPNI) samples, capable of efficiently screening billions of interactions. By using our TPPNI in training the UPNA-PPI model, we improve PPI prediction generalizability and interpretability, particularly in identifying potential binding sites locations on amino acid sequences, strengthening the prioritization of screening assays and facilitating the transferability of ML predictions across protein families and homodimers. UPNA-PPI establishes the foundation for a fundamental negative sampling methodology in graph machine learning by integrating insights from network topology. AVAILABILITY AND IMPLEMENTATION: Code and UPNA-PPI predictions are freely available at https://github.com/alxndgb/UPNA-PPI.

Indexed as

Computational BiologyMachine LearningProtein Interaction MappingProteinsBinding SitesDatabases, ProteinHumansProtein BindingProteins

Identifiers

PMID40193392
PMCPMC12080959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.